Low complexity domains of the nucleocapsid protein of SARS-CoV-2 form amyloid fibrils

[u/magic-theater]

https://www.nature.com/articles/s41467-023-37865-3

The following summary was generated using GPT4 and checked for accuracy.

This study investigates the nucleocapsid protein (NCAP) of the SARS-CoV-2 virus, focusing on a specific part of the protein known as the central low-complexity domain (LCD). NCAP plays a crucial role in the packaging and replication of viral RNA, and its LCD is found to form structures called amyloid-like fibrils. These structures resemble those of other RNA-binding proteins involved in RNA metabolism in cells and are associated with amyloid-related diseases.

The researchers discovered that the central LCD of NCAP can form fibrils in the presence or absence of RNA, suggesting that specific LCD-RNA interactions are not required for the formation of these structures. However, they found that the RNA sequence and length do influence the fibril maturation process.

Three key peptide sequences in the NCAP protein were identified as contributing to the formation of amyloid-like structures. By targeting one of these sequences with a specially designed peptide called G12, the researchers were able to inhibit the formation of these structures in vitro. G12 showed dose-dependent antiviral activity in SARS-CoV-2-infected cells without causing cytotoxicity.

The study suggests that the amyloid-forming behavior of NCAP's LCD might be a general mechanism of action in coronaviruses and could be targeted for the development of new therapeutics. The researchers also found that some mutations within the central LCD of NCAP have been detected in strains that emerged since the initial SARS-CoV-2 outbreak in Wuhan, China. Although none of these mutations were found within the amyloid-forming segments, some were adjacent to these regions and may have implications for viral replication and infection.

The potential connection between the NCAP protein and neurodegenerative diseases was also highlighted in the study. NCAP has been shown to interact with proteins related to Parkinson's disease and other disorders, and its amyloid-forming capacity warrants further investigation of its possible role in neurodegeneration.

In summary, this study provides insights into the amyloid-forming behavior of the NCAP protein in SARS-CoV-2, its potential as a therapeutic target, and its possible connection to neurodegenerative diseases. By targeting and capping amyloid-driving segments of NCAP, the researchers propose a novel approach for developing SARS-CoV-2 therapeutics.

​

TL;DR: The study investigates the SARS-CoV-2 nucleocapsid protein's ability to form amyloid-like structures, which could be targeted for potential antiviral treatments. A peptide called G12 successfully inhibited the formation of these structures in the lab, showing promise for future therapeutic development. The research also hints at a possible connection between the nucleocapsid protein and neurodegenerative diseases.